Products for Research Use Only

RI-AG03 (acetate)

CAT: 0804-HY-P10861A-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P10861A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RI-AG03 acetate is the acetate of RI-AG03. RI-AG03 is an orally active and a BBB-penetrable Tau aggregation peptide inhibitor. RI-AG03 inhibits Tau aggregation and improves associated neurodegeneration and behavioral phenotypes in both in vivo and in vitro models. RI-AG03 can be used in the study of tauopathies such as Alzheimer's disease[1][2].
UNSPSC
12352209
Target
Tau Protein
Related Pathways
Neuronal Signaling
Field of Research
Neurological Disease
Purity
98.22
Solubility
DMSO : 2.5 mg/mL (ultrasonic)
Smiles
[Ac-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-Gly-{d-Pro}-{d-Lys}-{d-Tyr}-{d-Lys}-{D-Ile}-{d-Gln}-{d-Val}-Gly-{d-Arg}-NH2(acetatesalt)]
Molecular Formula
C104H189N49O22·xC2H4O2
Molecular Weight
2477.93 (free base)
References & Citations
[1]Di Natale G, et al. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease? Molecules. 2022 Aug 9;27 (16) :5066.|[2]Aggidis A, et al. A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. Alzheimers Dement. 2024 Nov;20 (11) :7788-7804.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported